Search
IGC Pharma Inc
IGCAdd to Watchlist
0.276USD
+0.004+1.47%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
27.50MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-01The current earnings forecast score of IGC Pharma Inc is 8.00, ranking 166 out of 387 in the Biotechnology & Medical Research industry. The average price target is 3.62, with a high of 4.25 and a low of 3.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
4.000
Target Price
+1370.59%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
IGC Pharma Inc
IGC
2
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is IGC Pharma Inc's expected revenue for the next quarter?
IGC Pharma Inc's expected revenue is 246.00K.
What is IGC Pharma Inc's price target?
Analysts forecast that IGC Pharma Inc's price target is USD 3.62, with the highest forecast at USD 4.25 and the lowest forecast at USD 3.00.
How have IGC Pharma IncIGC's recent earnings per share performed?
The market expectation was USD -0.02, while IGC Pharma IncIGC's earnings per share (EPS) for the previous quarter was USD -0.02. EPS for the next quarter is expected at USD -0.02.
What is the analyst rating for IGC Pharma Inc?
Based on the ratings of IGC Pharma Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.